leadf
logo-loader
viewArecor

Arecor advancing today’s therapies to enable healthier lives

Snapshot

  • Arecor uses its ground-breaking technology platform, Arestat™ to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
  • Proprietary portfolio includes first franchise in diabetes and has expanded its development pipeline into anti-infectives
  • Partners with leading pharmaceutical and biotech companies to improve their products, find solutions or create next-generation products
Arecor -

What Arecor does

Arecor Limited, a private biopharmaceutical company, is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapies using its proprietary Arestat technology.  

Arestat is a world-leading, innovative formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides and has the unique potential to deliver superior formulations of both new and existing products which would otherwise not be possible.

It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.

 

How it is doing

In October, Arecor expanded its agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product.

The new deal builds on an earlier agreement signed in January to develop a product using Arecor’s proprietary drug formulation technology platform Arestat.

Hikma is expected to file the product covered by this latest agreement for approval with the US Food and Drug Administration in 2023.

Arecor will receive an upfront payment and further payments on the achievement of development, regulatory and commercial milestones, while Hikma will be responsible for the manufacture and commercialisation of the product.

 

What the boss says: Sarah Howell, chief executive

“Our track record in developing ready-to-administer medicines is further strengthened by this second agreement with Hikma. This growing partnership supports both companies’ product development strategies to bring enhanced products to market that simplify care and improve patient outcomes.”  

 

Video

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Arecor licenses first formulation to partner Inhibrx, taking their lung...

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Katie Pilbeam about their peer review paper on their first clinical trial of proprietary product, AT247, which has been published in the prestigious medical journal Diabetes Care. In terms of news flow, their first patient has...

4 weeks, 2 days ago

2 min read